Other languages Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
13.74 ^USD	+3.70%		+4.49%	+46.01%

01:00pm	Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer	CI
Feb. 09	Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer	07:00am
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024	Dec. 26
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Nov. 24
Sector Update: Health Care	Nov. 24
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 20
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 20
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-07
Enanta Pharmaceuticals Says Phase 1 Clinical Study of Oral L-Protein Inhibitor EDP-323 Yields 'Positive' Topline Data	23-06-20
Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus	23-06-20
Top Midday Decliners	23-05-09
Looming Inflation Report, Weak Chinese Data Drive Premarket Losses for US Equity Futures	23-05-09
Top Premarket Decliners	23-05-09
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-08
Sector Update: Health Care Stocks Declining Late Tuesday	23-04-25
Sector Update: Health Care	23-04-25
Enanta Pharmaceuticals Sells Part of Future Royalties of Mavyret Global Sales to OMERS for $200 Million	23-04-25
Enanta Pharmaceuticals Says FDA Grants Fast Track Designation for EDP-323	23-04-06
Insider Sell: Enanta Pharmaceuticals	23-03-15
Enanta Pharmaceuticals, Inc. to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research	23-03-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Other languages

Filters